Related Topic: Development of a Transdermal Drug Delivery System Using Self-Dissolving Microneedle Arrays Fabricated with Hyaluronic Acid

  • Hidemasa KatsumiEmail author
  • Ying-Shu Quan
  • Fumio Kamiyama
  • Akira Yamamoto


Microneedle arrays (MNs) are micron-scale needles assembled on a transdermal patch. They are a novel and minimally invasive approach for transdermal drug delivery. MNs are capable of creating superficial pathways across the skin for small drugs, macromolecules, nanoparticles, or fluid extractions to achieve enhanced drug delivery. Needles with micrometer dimensions are long enough to penetrate the stratum corneum; by controlling the length of the needles, the skin can be penetrated to a precise depth. Based on design and materials, MNs are roughly divided into the following groups: (i) solid MNs, (ii) coated MNs, (iii) hollow MNs, and (iv) dissolving MNs. We recently focused on dissolving MNs, because of the advantages of direct drug delivery along with the dissolution of the needle in the skin. The materials for such MNs are often safe and non-toxic to the skin. In our study, hyaluronic acid (HA), a common ingredient in skincare products, was found to produce MNs with high biocompatibility and resistance to deformation. The resulting MNs were strong enough to reliably pierce the skin, dissolve, and rapidly release the contained drug into the skin. Furthermore, the absence of a heating step and organic solvents during fabrication proved to be a notable advantage in preserving the stability of incorporated drugs. In this chapter, recent challenges in the development of new transdermal drug delivery systems using dissolving HA MNs are summarized. Future prospects of HA MNs are also discussed in terms of clinical application.


Transdermal drug delivery Microneedle arrays Hyaluronic acid Peptide and protein drugs Insulin Alendronate Exendin-4 Diabetes Osteoporosis 


  1. 1.
    Chen H, Zhu H, Zheng J et al (2009) Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin. J Control Release 139:63–72CrossRefPubMedGoogle Scholar
  2. 2.
    Martanto W, Davis SP, Holiday NR et al (2004) Transdermal delivery of insulin using microneedles in vivo. Pharm Res 21:947–952CrossRefPubMedGoogle Scholar
  3. 3.
    Kusamori K, Katsumi H, Sakai R et al (2015) Development of a drug-coated microneedle array and its application for transdermal delivery of interferon alpha. Biofabrication (in press)Google Scholar
  4. 4.
    Nordquist L, Roxhed N, Griss P et al (2007) Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration. Pharm Res 24:1381–1388CrossRefPubMedGoogle Scholar
  5. 5.
    McAllister DV, Wang PM, Davis SP et al (2003) Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci U S A 100:13755–13760CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Wang PM, Cornwell M, Hill J et al (2006) Precise microinjection into skin using hollow microneedles. J Invest Dermatol 126:1080–1087CrossRefPubMedGoogle Scholar
  7. 7.
    Katsumi H, Liu S, Tanaka Y et al (2012) Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: evaluation of transdermal absorption, safety, and pharmacological effects after application in rats. J Pharm Sci 101:3230–3238CrossRefPubMedGoogle Scholar
  8. 8.
    Liu S, Jin MN, Quan YS et al (2012) The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin. J Control Release 161:933–941CrossRefPubMedGoogle Scholar
  9. 9.
    Liu S, Jin MN, Quan YS et al (2014) Transdermal delivery of relatively high molecular weight drugs using novel self-dissolving microneedle arrays fabricated from hyaluronic acid and their characteristics and safety after application to the skin. Eur J Pharm Biopharm 86:267–276CrossRefPubMedGoogle Scholar
  10. 10.
    Wu D, Quan YS, Kamiyama F et al (2015) Improvement of transdermal delivery of sumatriptan succinate using a novel self-dissolving microneedle array fabricated from sodium hyaluronate in rats. Biol Pharm Bull 38:365–373CrossRefPubMedGoogle Scholar
  11. 11.
    Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Porras AG, Holland SD, Gertz BJ (1999) Pharmacokinetics of alendronate. Clin Pharmacokinet 36:315–328CrossRefPubMedGoogle Scholar
  13. 13.
    Liu S, Wu D, Quan YS et al (2016) Improvement of transdermal delivery of exendin-4 using novel tip-loaded microneedle arrays fabricated from hyaluronic acid. Mol Pharm 13:272–279Google Scholar

Copyright information

© Springer Japan KK 2017

Authors and Affiliations

  • Hidemasa Katsumi
    • 1
    Email author
  • Ying-Shu Quan
    • 1
    • 2
  • Fumio Kamiyama
    • 2
  • Akira Yamamoto
    • 1
  1. 1.Department of BiopharmaceuticsKyoto Pharmaceutical UniversityKyotoJapan
  2. 2.CosMED Pharmaceutical Company, LtdKyotoJapan

Personalised recommendations